​​​​​​​PsA Treatment Options Expand - Takeaways - MDSpire

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

  • By

  • Kathryn Wighton

  • March 9, 2026

  • 3 min

Share

  • 1

    Deucravacitinib (Sotyktu) is the first TYK2 inhibitor approved for adults with active psoriatic arthritis by the FDA.

  • 2

    The drug demonstrated improved disease activity outcomes in two phase 3 trials compared to placebo.

  • 3

    In the POETYK PsA-1 trial, 54% of patients on deucravacitinib achieved ACR20 response versus 34% on placebo.

  • 4

    The safety profile of deucravacitinib was consistent with previous studies, with common adverse reactions including upper respiratory infections.

  • 5

    Deucravacitinib selectively inhibits TYK2 signaling, affecting interleukin-23, interleukin-12, and type 1 interferon pathways.

Original Source(s)

​​​​​​​PsA Treatment Options Expand

  • by Kathryn Wighton

  • March 9, 2026

Related Content

Bimekizumab in Psoriasis: 3-Year Outcomes

Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Differences in clinical features between axial psoriatic arthritis and axial spondyloarthritis: a systematic review and meta-analysis of observational studies